|
Ras peptides
|
Amino acid sequence
|
Vaccinated patients by arm
|
|---|
| |
5 6 7 8 9 10 11 12 13 14 15 16 17
| |
|---|
|
ras 5-17
|
Lys- Leu-Val- Val- Val- Gly- Ala- Gly- Gly- Val- Gly- Lys- Ser
|
Nome
|
|
(wild type)
| | |
|
ras 5-17
|
Lys- Leu-Val- Val- Val- Gly- Ala- Asp- Gly- Val- Gly- Lys- Ser
|
A: 1-4, 9-12, 14, 16
|
|
(Gly→Asp)
| |
B: 3-6, 8-10, 14-16
|
| | |
C: 1-5, 7, 9-11, 13-19
|
|
ras 5-17
|
Lys- Leu-Val- Val- Val- Gly- Ala- Val- Gly- Val- Gly- Lys- Ser
|
A: 5, 6, 15
|
|
(Gly→Val)
| |
B: 1, 7, 11, 12, 17, 18
|
| | |
C: 6, 12
|
|
ras 5-17
|
Lys- Leu-Val- Val- Val- Gly- Ala- Cys- Gly- Val- Gly- Lys- Ser
|
A: 7, 8, 13
|
|
(Gly→Cys)
| |
B: 2, 13
|
| | |
C: 8
|
- The peptides used in the study were 13-mer peptides (residues 5-17) corresponding to the tumor Ras mutations. Corresponding mutant part of the peptide is bolded.
